This has excitingly led to another combination therapy in the pipeline that utilises the alternate anti-obesity actions of amylin with the well-established class of GLP-1 mimetic; Cagrilintide with Semaglutide. Here, IAPP is linked to obesity due to melanocortin 4 receptor deficiency.